Abstract
Two human non-small cell lung cancer xenograft lines were used to study the activity of combina tions of 2 cytotoxic drugs with human alpha-2 interferon. Statistically significant potentiation of cisplatin and ifosfamide given weekly for 5 weeks in a low dose was seen when recombinant human alpha interferon (rHu IFN-alpha 2b) was administered simultaneously (2×104 U/mouse/day). Median doubling time for cisplatin treated tumours increased from 17 and 14 days to 27 and 18.5 days with the addition of interferon, whereas for ifosfamide they increased from 11.5 and 14 days to 15 and 16 days. Human alpha-2 interferon at this dose had no effect as a single agent.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Souhami RL: The management of advanced non-small cell carcinoma of the bronchus. In: Smyth JF (ed) The management of lung cancer. London: Edward Arnold 1984:132–149
Gralla RJ, Casper ES, Kelsen DP, Braun DW, Dukeman ME, Martini N, Young CW and Golbey RB: Cisplatin and vindesine combination chemotherapy for advanced carci noma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 1981 (95): 414–420
Carmichael J, Gregor A, Cornbleet MA, Allan SG, Mclntyre MA, Grant IWB, Crompton GK, Leonard RCF and Smyth JF: Vindesine and cis-platinum in the treatment of non-small cell lung cancer. Eur J Cancer Clin Oncol 1985 (21): 811–814
Souhami RL: Chemotherapy in non-small cell bronchial carcinoma. Thorax 1985 (40): 641–645
Quesada JR, Swanson DA, Trinidade A and Gutterman JU: Renal cell carcinoma: anti-tumour effects of leukocyte interferon. Cancer Res 1983 (43): 940–947
Merigan TC, Sikora C, Breeden JH, Levy R and Rosenberg SA: Preliminary observations of the effect of human leukocyte interferon in non-Hodgkin’s lymphoma. N Engl J Med 1978 (299): 1449–1453
Quesada JR, Reuben J, Manning JT, Hersh EM and Gutterman JU: Alpha interferon for induction of remission of hairy-cell leukemia. N Engl J Med 1984 (310): 15–18
Real FX, Krown SE, Krim M, Myskowski PL, Safai B and Oettgen HR: Treatment of Kaposi’s sarcoma with recombinant leukocyte A interferon. Proc Am Soc Clin Oncol 1984 (3): 55
Grunberg SM, Kempf RA, Itri LM, Venturi CL, Boswell WD and Mitchell MS: Phase II study of recombinant alpha interferon in the treatment of advanced non-small cell lung carcinoma. Cancer Treat Rep 1985 (69): 1031–1032
Figlin RA and Sarna GP: Human leukocyte interferon: phase II trial in non-small cell lung cancer and adenocarcinoma of the colon/rectum. Proc Am Soc Clin Oncol 1983 (2): 45
Leavitt RD, Duffey P and Aisner J: A phase II study of recombinant leukocyte-A interferon in non-small cell carcinoma of the lung. Proc Am Soc Clin Oncol 1984 (3): 52
Ernst P, Olesen BK, Nissen MH, Hokland P, Justesen J and Hansen HH: In vivo effect of recombinant interferon alpha in patients with lung cancer. Proc Am Soc Clin Oncol 1984 (3): 66
Aapro MS, Alberts DS and Salmon SE: Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumours in a clonogenic assay. Cancer Chemother Pharmacol 1983 (10): 161–166
Welander CE, Morgan TM, Homelsey HD, Trotta PP and Spiegel RJ: Combined recombinant human interferon alpha-2 and cytotoxic agents studied in a clonogenic assay. Int J Cancer 1985 (35): 721–729
Chirigos MA and Pearson JW: Cure of murine leukemia with drug and interferon treatment. J Natl Cancer Inst 1973 (51): 1367–1368
Gresser I, Maury C and Tovey M: Efficacy of combined interferon-cyclophosphamide therapy after diagnosis of lymphoma in AKR mice. Eur J Cancer 1978 (14): 97–99
Balkwill FR and Moodie EM: Positive interactions between human interferon and cyclophosphamide or adriamycin in a human tumor model system. Cancer Res 1984 (44): 904–908
Steel GG, Courtenay VD and Rostom AY: Improved immunosuppression techniques for the xenografting of human tumours. Br J Cancer 1978 (37): 224–230
Fergusson RJ, Carmichael J and Smyth JF: Human tumour xenografts growing in immunodeficient mice: a useful model for assessing chemotherapeutic agents in bronchial carcinoma. Thorax 1986 (41): 376–380
Freireich EJ, Gehan RA, Rail DA, Schmidt LH and Skipper HE: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. Cancer Chemother Rep 1966 (50): 219–244
Kopper L and Steel GG: The therapeutic response of three human tumor lines maintained in immune-suppressed mice. Cancer Res 1975 (35): 2704–2713
Shorthouse AJ, Peckham MJ, Smyth JR and Steel GG: The therapeutic response of bronchial carcinoma xenografts: a direct patient-xenograft comparison. Br J Cancer 1980 (41): 142–145
Djeu JY, Heinbaugh JA, Holden HT and Heberman RB: Augmentation of mouse natural killer cell activity by interferon and interferon inducers. J Immunol 1979 (122): 175–181
Singh G, Renton KW and Stebbing N: Homogenous interferon from E.Coli depresses hepatic cytochrome P-450 and drug biotransformation. Biochem Biophys Res Commun 1982 (106): 1256–1261
Balkwill FR, Moodie EM, Freedman V and Fantes KH: Human interferon inhibits the growth of established human breast tumours in nude mice. Int J Cancer 1982 (30): 231–235
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Fergusson, R.J., Smyth, J.F. (1988). The Effect of Interferon-Alpha on the Activity of Cytotoxic Drugs in Bronchial Carcinoma Xenografts. In: Winograd, B., Peckham, M., Pinedo, H.M. (eds) Human Tumour Xenografts in Anticancer Drug Development. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-73252-2_18
Download citation
DOI: https://doi.org/10.1007/978-3-642-73252-2_18
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-73254-6
Online ISBN: 978-3-642-73252-2
eBook Packages: Springer Book Archive